Cite
Kuusanmäki H, Dufva O, Parri E, et al. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget. 2017;8(57):97516-97527doi: 10.18632/oncotarget.22178.
Kuusanmäki, H., Dufva, O., Parri, E., van Adrichem, A. J., Rajala, H., Majumder, M. M., Yadav, B., Parsons, A., Chan, W. C., Wennerberg, K., Mustjoki, S., & Heckman, C. A. (2017). Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget, 8(57), 97516-97527. https://doi.org/10.18632/oncotarget.22178
Kuusanmäki, Heikki, et al. "Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling." Oncotarget vol. 8,57 (2017): 97516-97527. doi: https://doi.org/10.18632/oncotarget.22178
Kuusanmäki H, Dufva O, Parri E, van Adrichem AJ, Rajala H, Majumder MM, Yadav B, Parsons A, Chan WC, Wennerberg K, Mustjoki S, Heckman CA. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget. 2017 Oct 31;8(57):97516-97527. doi: 10.18632/oncotarget.22178. eCollection 2017 Nov 14. PMID: 29228628; PMCID: PMC5722580.
Copy
Download .nbib